Disposition of 42553 shares by Daniel Karp of Organon subject to Rule 16b-3
| OGN Stock | USD 8.98 0.16 1.75% |
About 55% of Organon's investors are presently thinking to get in. The analysis of overall sentiment of trading Organon Co stock suggests that some investors are interested at this time. Organon's investing sentiment overview a quick insight into current market opportunities from investing in Organon Co. Many technical investors use Organon stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Filed transaction by Organon Co Officer: Executive Vp, Corp. Dev.. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at thelincolnianonline.com
 |
Organon Maximum Pain Price Across July 18th 2025 Option Contracts
Organon's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Organon close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Organon's options.
Organon Fundamental Analysis
We analyze Organon's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Organon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Organon based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
Organon is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Organon Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Organon stock to make a market-neutral strategy. Peer analysis of Organon could also be used in its relative valuation, which is a method of valuing Organon by comparing valuation metrics with similar companies.
Peers
Organon Related Equities
| PFE | Pfizer | 0.34 | ||||
| AMGN | Amgen | 0.19 | ||||
| AZN | AstraZeneca PLC | 0.11 | ||||
| SNY | Sanofi ADR | 0.19 | ||||
| JNJ | Johnson Johnson | 0.48 | ||||
| BIIB | Biogen | 0.69 | ||||
| NVS | Novartis | 0.88 | ||||
| ABBV | AbbVie | 1.02 | ||||
| MRK | Merck | 1.24 | ||||
| LLY | Eli Lilly | 1.25 | ||||
| BMY | Bristol Myers | 1.45 | ||||
| GILD | Gilead Sciences | 1.46 |
Check out Organon Hype Analysis, Organon Correlation and Organon Performance. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organon. If investors know Organon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Dividend Share 1.12 | Earnings Share 2.88 | Revenue Per Share | Quarterly Revenue Growth (0.07) |
The market value of Organon is measured differently than its book value, which is the value of Organon that is recorded on the company's balance sheet. Investors also form their own opinion of Organon's value that differs from its market value or its book value, called intrinsic value, which is Organon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organon's market value can be influenced by many factors that don't directly affect Organon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Organon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.